A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination with Pembrolizumab in Patients with Percutaneously Accessible Lesions with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy

ORR, defined as the proportion of patients who achieved PR and/or CR per local Investigator assessment using RECIST version 1.1, CBR, defined as the proportion of patients who respond to treatment, estimated as the proportion of patients who achieve SD, PR, or CR per local Investigator assessment using iRECIST., OS, evaluated as time from baseline until death.